Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 11;21(1):133-139.
doi: 10.1007/s40200-021-00947-4. eCollection 2022 Jun.

Effects of the TCF7L2 and KCNQ1 common variant on sulfonylurea response in type 2 diabetes mellitus patients: a preliminary pharmacogenetic study

Diba Dianatshoar  1 , Tara Alidaee  1 , Negar Sarhangi  2 , Mahdi Afshari  3 , Hamid Reza Aghaei Meybodi  4 , Mandana Hasanzad  1   2
Affiliations

Effects of the TCF7L2 and KCNQ1 common variant on sulfonylurea response in type 2 diabetes mellitus patients: a preliminary pharmacogenetic study

Diba Dianatshoar et al. J Diabetes Metab Disord. .

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a common chronic condition characterized by high blood glucose levels which is caused by genetic and environmental factors. Currently, pharmacogenomics (PGx) is anticipated to enable the development of personalized treatment in a wide range of health issues. Sulfonylureas (SFUs) are among the oral anti-diabetic drugs that are very popular due to their low cost. Genetic variants in transcription factor 7 like 2 (TCF7L2) and potassium voltage-gated channel subfamily Q member 1 (KCNQ1) have been reported for altered therapeutic response to sulfonylurea. The aim of the present study is to evaluate any association between common genetic variant of the TCF7L2 and KCNQ1 (rs7903146 and rs2237892, respectively) and the response to sulfonylurea in a group of Iranian patients for the first time.

Methods: Genotyping was carried out in 30 T2DM patients who received sulfonylurea treatment for more than two months in addition to previous medication using the Sanger sequencing method.

Results: In 30 T2DM patients who received SFUs treatment, 60%, 33.3% and 6.7% had CC, CT and TT genotypes, respectively. After treatment, adjusted fasting blood sugar (FBS) mean reduction level in CT and TT carriers was lower than CC carriers. Adjusted hemoglobin A1c (HbA1c) mean reduction level was also lower in CT and TT compared with CC carriers, but, none of these differences were statistically significant. Genotype frequencies of TT, CT and CC genotypes of rs2237892 variant of KCNQ1 gene were 0 (0%), 3 (10%) and 27 (90%) respectively. Patients with CT and CC genotypes of rs2237892 variant had also similar changes in FBS (P=0.200) and HbA1c (P=0.436) after treatment with SFUs.

Conclusions: Genotypes of TCF7L2 and KCNQ1 common variant did not show any impact on the treatment response among T2DM patients receiving SFUs.

Keywords: Sulfonylureas; T2DM; Transcription factor 7-like 2 variants.

PubMed Disclaimer

Conflict of interest statement

Competing of interestThere are no conflicts of interest declared by the authors.

Figures

Fig. 1
Fig. 1
Response to sulfonylurea treatment among T2DM patients with rs7903146 different genotypes. (A) Changes in mean FBS after sulfonylurea treatment; (B) Changes in mean HbA1c after sulfonylurea treatment
Fig. 2
Fig. 2
Response to sulfonylurea treatment among T2DM patients with rs2237892 different genotypes. (A) Changes in mean FBS after sulfonylurea treatment; (B) Changes in mean HbA1c after sulfonylurea treatment
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Stančáková A, Laakso M. Genetics of type 2 diabetes. Novelties Diabetes. 2016;31:203–20. doi: 10.1159/000439418. - DOI - PubMed
    1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21. doi: 10.1016/j.diabres.2011.10.029. - DOI - PubMed
    1. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008;77(11):1553–60. - PubMed
    1. Kadric SI, Cesic AK, Dujic T. Pharmacogenetics of new classes of antidiabetic drugs. Bosn J Basic Med Sci. 2021;21(6):659–671. - PMC - PubMed
    1. Mannino GC, Andreozzi F. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes Metab Res Rev. 2019;35(3):e3109. doi: 10.1002/dmrr.3109. - DOI - PMC - PubMed

LinkOut - more resources